Type 1 IGF receptor associates with adverse outcome and cellular radioresistance in paediatric high-grade glioma.
Loading...
Embargo End Date
ICR Authors
Authors
Simpson, AD
Soo, YWJ
Rieunier, G
Aleksic, T
Ansorge, O
Jones, C
Macaulay, VM
Soo, YWJ
Rieunier, G
Aleksic, T
Ansorge, O
Jones, C
Macaulay, VM
Document Type
Journal Article
Date
2020-03-01
Date Accepted
2019-11-19
Abstract
High-grade glioma (HGG) is highly resistant to therapy, prompting us to investigate the contribution of insulin-like growth factor receptor (IGF-1R), linked with radioresistance in other cancers. IGF-1R immunohistochemistry in 305 adult HGG (aHGG) and 103 paediatric/young adult HGG (pHGG) cases revealed significant association with adverse survival in pHGG, with median survival of 13.5 vs 29 months for pHGGs with moderate/strong vs negative/weak IGF-1R (p = 0.011). Secondly, we tested IGF-1R inhibitor BMS-754807 in HGG cells, finding minimal radiosensitisation of 2/3 aHGG cell lines (dose enhancement ratios DERs < 1.60 at 2-8 Gy), and greater radiosensitisation of 2/2 pHGG cell lines (DERs ≤ 4.16). BMS-754807 did not influence radiation-induced apoptosis but perturbed the DNA damage response with altered induction/resolution of γH2AX, 53BP1 and RAD51 foci. These data indicate that IGF-1R promotes radioresistance in pHGG, potentially contributing to the association of IGF-1R with adverse outcome and suggesting IGF-1R as a candidate treatment target in pHGG.
Citation
British journal of cancer, 2020, 122 (5), pp. 624 - 629
Source Title
Publisher
NATURE PUBLISHING GROUP
ISSN
0007-0920
eISSN
1532-1827
Collections
Research Team
Glioma Team